John Rotrosen MD

Psychiatry•New York, NY

Professor, Psychiatry, New York University School of Medicine

Join to View Full Profile

423 East 23 StPsychiatry VA NyhhsNew York, NY 10010
Phone+1 212-951-3294

Education & Training

NYU Grossman School of MedicineInternship, Transitional Year, 1973 - 1974
New York University School of MedicineClass of 1972

Certifications & Licensure

NY State Medical License 1976 - 2025
American Board of Psychiatry and Neurology Psychiatry

Clinical Trials

Buprenorphine and Naloxone for the Treatment of Opiate Dependence - 1 Start of enrollment: 1996 Apr 01
Completed
Phase 3
Modeling Impaired Judgement in Cocaine Abusers - 6 Start of enrollment: 1997 Mar 01
Completed
Phase 4
Prepulse Inhibition of Startle in Cocaine Dependence - 7 Start of enrollment: 1997 Feb 01
Completed
Phase 1
Buprenorphine and Naloxone Combination Study - 10 Start of enrollment: 1996 Nov 01
Completed
Phase 1
Impact of Exercise and Affirmations (IntenSati) on Addiction-related Cognitive and Psychosocial Deficits Start of enrollment: 2010 Jul 01
Completed
Not Applicable
Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment Start of enrollment: 2014 Jan 29
Completed
Phase 4
A Double-Blind Trial of Psilocybin-Assisted Treatment of Alcohol Dependence Start of enrollment: 2014 Jun 01
Completed
Phase 2
TAU Opioid Use Outcomes Following Discharge From Detoxification and Short Term Residential Programs Affiliated With CTN-0051 Start of enrollment: 2016 Jun 01
Completed
Join now to see all

Publications & Presentations

PubMed

Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone on treatment interruption: Comparing findings from a reanalysis of the X:BOT RCT...
Sara Lodi, Shapei Yan, Benjamin Bovell-Ammon, Paul J Christine, Heather E Hsu
Addiction. 2025-03-19
Effects of randomization to buprenorphine or naltrexone for OUD on cannabis use outcomes: A secondary analysis of the X:BOT trial.
Matisyahu Shulman, Tse-Hwei Choo, Kaitlyn Ohrtman, Martina Pavlicova, John Rotrosen
Drug and Alcohol Dependence. 2025-03-01
Optimizing retention strategies for opioid use disorder pharmacotherapy: The retention phase of the CTN-0100 trial (RDD).
Matisyahu Shulman, Sarah Meyers-Ohki, Patricia Novo, Scott Provost, Kaitlyn Ohrtman
Contemporary Clinical Trials. 2025-03-01

Journal Articles

Cost-Effectiveness of Buprenorphine–Naloxone Versus Extended-Release Naltrexone to Prevent Opioid Relapse
Joshua D Lee, John Rotrosen, Edward V Nunes, Annals of Internal Medicine
American Psychiatric Association Publishing
John Rotrosen, MD, PubMed

Press Mentions

Open-Label Placebo Improved Outcomes for People in Treatment for Opioid Use DisorderApril 12th, 2023
Psychedelic Drug Therapy May Help Treat Alcohol AddictionAugust 24th, 2022
Study Shows Two Addiction Medications Similar but Drop Out Rates High: Three Possible RemediesNovember 27th, 2017
Join now to see all